Patients undergo radiation therapy on days 1 and 2. Within 12 hours of the completion of radiation therapy, patients receive TLR9 agonist SD-101 intratumorally (IT) on day 2 and on days 9, 16, 23, and 30. Patients also receive ibrutinib orally (PO) daily beginning on day 10 for 96 weeks in the absence of disease progression or unexpected toxicity.